Kliniken &… Kliniken Kopfklinik… Neurochirurgische… Forschung Experimentelle… AG Präzisionsmedizin…

AG PRÄZISIONSMEDIZIN FÜR AGGRESSIVE MENINGEOME

PRECISION MEDICINE FOR AGGRESSIVE MENINGIOMAS

Overview

Meningiomas are usually considered benign brain tumors, however, up to one-third can display an aggressive behavior resulting in recurrence and accelerated tumor growth. The treatment consists of surgical resection and/or radiotherapy. However, to date, there are no systemic treatment options for patients.

Therefore, our group focuses on:

  1. Development of novel preclinical and clinical models for meningioma research (e.g., patient-derived tumor organoids).
  2. Advancing of automated and personalized drug screenings.
  3. Identification of treatment-associated biomarkers.
  4. Deciphering the molecular mechanisms of effective drugs.

Team

Wiss. Mitarbeiter/-innen

  • Derin Nalcakan
  • Yimin Pan

SELECTED PUBLICATIONS

  • Jungwirth G, Yu T, Liu F, Cao J, Alaa Eddine M, Moustafa M, Abdollahi A, Warta R, Unterberg A, Herold-Mende C. Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas. Clin Cancer Res. 2023 Jan 4;29(1):233-243. doi: 10.1158/1078-0432.CCR-22-2085.PMID: 36282277
  • Jungwirth G, Hanemann CO, Dunn IF, Herold-Mende C. Preclinical Models of Meningioma. Adv Exp Med Biol. 2023;1416:199-211. doi: 10.1007/978-3-031-29750-2_15.PMID: 37432629
  • Jungwirth G, Yu T, Moustafa M, Rapp C, Warta R, Jungk C, Sahm F, Dettling S, Zweckberger K, Lamszus K, Senft C, Loehr M, Keßler AF, Ketter R, Westphal M, Debus J, von Deimling A, Simon M, Unterberg A, Abdollahi A, Herold-Mende C. Identification of KIF11 As a Novel Target in Meningioma. Cancers (Basel). 2019 Apr 15;11(4):545. doi: 10.3390/cancers11040545.PMID: 30991738
  • Jungwirth G, Yu T, Cao J, Eddine MA, Moustafa M, Warta R, Debus J, Unterberg A, Abdollahi A, Herold-Mende C. KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. Cancer Lett. 2021 May 28;506:1-10. doi: 10.1016/j.canlet.2021.02.016. Epub 2021 Feb 27.PMID: 33652084
  • Yu T, Cao J, Alaa Eddine M, Moustafa M, Mock A, Erkut C, Abdollahi A, Warta R, Unterberg A, Herold-Mende C, Jungwirth G. Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. Cancers (Basel). 2021 Nov 24;13(23):5898. doi: 10.3390/cancers13235898.PMID: 34885009
  • Jungwirth G, Warta R, Beynon C, Sahm F, von Deimling A, Unterberg A, Herold-Mende C, Jungk C. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathol Commun. 2019 Aug 30;7(1):140. doi: 10.1186/s40478-019-0793-4.PMID: 31470906